GGrantIndex
← Leaderboards

Kurt A Schalper

Emory University

Google Scholar ↗PubMed ↗ORCID ↗
$6,187,130
Attributed
$7,191,738
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY2019–25
$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,191,738 · 8

By mechanism

R01$2,864,666 · 2
R37$2,610,977 · 1
P50$801,738 · 2
R21$478,532 · 1
UH2$251,360 · 1
R03$184,465 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Tumor”

Research focus

TumorMalignant Neoplasm Of LungImmuneCellsResponseProgrammed Cell Death Protein 1ResourcesResistancePathway InteractionsMalignant NeoplasmsPatient SelectionCancer ImmunotherapyMediatingMortalityMapsClinical TrialsImageClinically SignificantImmune EvasionClinicLungImmunoregulationImmunotherapyBiological Markers

Grant awards (19)

Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$722,919
R37 · FY2025 · CA · contact PI
Biological and clinical significance of spatial immune heterogenenity in non-small cell lung cancer$478,532
R21 · FY2025 · CA · contact PI
Project 1: Targeting Tumor Phospholipase PLA2G10 for Cancer Immunotherapy$411,417
P50 · FY2025 · CA · contact PI
Core C: Biospecimen and Biomarker Core$390,321
P50 · FY2025 · CA · contact PI
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer$383,156
R01 · FY2025 · CA · contact PI
Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.$251,360
UH2 · FY2025 · CA · contact PI
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer$363,999
R01 · FY2024 · CA · contact PI
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$363,815
R37 · FY2024 · CA · contact PI
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$552,153
R01 · FY2023 · CA
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer$375,493
R01 · FY2023 · CA · contact PI
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$375,309
R37 · FY2023 · CA · contact PI
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$431,216
R01 · FY2022 · CA
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$382,973
R37 · FY2022 · CA · contact PI
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer$375,493
R01 · FY2022 · CA · contact PI
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer$383,156
R01 · FY2021 · CA · contact PI
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$382,978
R37 · FY2021 · CA · contact PI
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung Cancer$382,983
R37 · FY2020 · CA · contact PI
ROLE OF THE HLA ANTIGEN PRESENTING MACHINERY (APM) IN RESISTANCE TO PD-1 AXIS BLOCKADE IN NON-SMALL CELL LUNG CANCER$83,795
R03 · FY2020 · CA · contact PI
ROLE OF THE HLA ANTIGEN PRESENTING MACHINERY (APM) IN RESISTANCE TO PD-1 AXIS BLOCKADE IN NON-SMALL CELL LUNG CANCER$100,670
R03 · FY2019 · CA · contact PI